Lymph node metastases develop when malignant cells from a primary tumor invade the lymphatic system and establish metastatic deposits in regional or distant lymph nodes. Lymphatic dissemination is one of the most common pathways of spread in solid malignancies and has major prognostic and therapeutic implications.
Within the TNM classification, lymph node involvement is represented by the N category:
In addition, lymph nodes may be involved as part of distant metastatic disease and, depending on the primary tumor and nodal location, may therefore constitute M1 disease.
Lymph node metastases are frequently asymptomatic initially and are detected during structured oncological surveillance. Clinical manifestations arise predominantly from local mass effect or compression of adjacent anatomical structures and therefore vary according to the lymph node region involved.
The complete absence of symptoms despite imaging-confirmed nodal recurrence is a common reason why such lesions may remain clinically occult. Regular oncological follow-up is therefore essential to facilitate timely initiation of treatment.
The diagnostic work-up for suspected lymph node metastases is designed to define the exact location, extent, and number of involved nodal stations, identify the primary malignancy, and, where necessary, obtain histopathological confirmation. These findings form the basis of all subsequent therapeutic decisions.
The management of lymph node metastases is multimodal and is individualized within an interdisciplinary tumor board. Key determinants include the primary malignancy, number and location of involved lymph nodes, previous treatments, and the patient's overall clinical condition.
Stereotactic body radiotherapy (SBRT) is assuming an increasingly important role in the treatment of lymph node metastases, particularly in patients with oligometastatic nodal recurrence. The technique permits millimeter-precision irradiation of individual lymph nodes using high doses per fraction while minimizing radiation exposure to the surrounding normal tissues.
The CyberKnife system is a robotically guided linear accelerator that delivers radiation from hundreds of beam angles. Integrated image guidance continuously detects and compensates for patient movement in real time without rigid mechanical fixation. This allows highly precise dose delivery to deeply located nodal regions, including paraaortic, pelvic, and mediastinal lymph nodes, while respecting dose constraints for adjacent critical structures such as the spinal cord, kidneys, ureters, and bowel.
One important application of CyberKnife® treatment for lymph node metastases is nodal recurrence of prostate cancer. Following curative-intent treatment, such as radical prostatectomy or radiotherapy, a substantial proportion of patients develop biochemical recurrence characterized by a rising PSA level. Modern PSMA PET/CT can identify very small nodal metastases even at PSA concentrations below 0.5 ng/mL. Prospective studies of metastasis-directed therapy, including STOMP and ORIOLE, have shown that targeted treatment of oligometastatic lesions can delay disease progression and defer the need for systemic androgen-deprivation therapy in appropriately selected patients, thereby potentially preserving quality of life.
In oligometastatic nodal disease—meaning a limited number of clearly delineated involved lymph nodes—a curative-intent approach with CyberKnife® may be considered in selected patients. Clinical studies of metastasis-directed therapy demonstrate durable disease control in a proportion of appropriately selected patients. In more extensive nodal disease, treatment is generally directed toward prolonging disease control, delaying systemic treatment where appropriate, and preserving quality of life.
Yes, re-irradiation is feasible in many carefully selected cases. A principal advantage of SBRT is its ability to concentrate the prescribed dose within the target volume while producing a steep dose fall-off in surrounding tissues. Previous radiation exposure must be incorporated into treatment planning, and strict cumulative dose constraints are applied to critical organs such as the spinal cord, kidneys, and small bowel. The indication is determined individually by the interdisciplinary team.
As a rule, 1–3 involved lymph node stations may be treated within a CyberKnife® treatment course. With appropriate treatment planning, up to approximately five lesions may be irradiated during one treatment cycle. The final decision depends on lesion location and size, proximity to critical structures, total target volume, and the patient's overall condition.
Conventional nodal radiotherapy—for example pelvic or mediastinal irradiation—generally encompasses larger target volumes and is delivered over approximately 25–35 fractions across several weeks. SBRT, by contrast, selectively targets the radiographically evident involved lymph node in 3–5 high-dose fractions. This substantially shortens the treatment course and limits radiation exposure to surrounding normal tissues, while also facilitating additional focal treatment should recurrence subsequently occur at another nodal site.
PSMA PET/CT is currently the most sensitive imaging modality for detecting lymph node metastases in recurrent prostate cancer and can identify lesions at very low PSA concentrations, including levels below 0.5 ng/mL. It enables precise localization of involved nodal stations and provides an essential imaging basis for metastasis-directed stereotactic treatment. Without PSMA PET/CT, many small-volume nodal recurrences would remain occult on conventional imaging.
We Will Advise You on Your Treatment Options
Whether you have nodal recurrence after prostate cancer, mediastinal metastases, or oligometastatic involvement of several nodal stations, the ERCM team will review your individual case and advise you on the potential role of stereotactic radiosurgery.